Challenges and Progress in Advanced Imaging for Prostate Cancer

Overview of hurdles and advancements in utilizing advanced imaging techniques for prostate cancer diagnosis, including agent availability, scheduling, facility preferences, and reimbursement.

EP: 1.An Overview of PSMA-PET Scans and Prostate Cancer Imaging

EP: 2.Advancements in Prostate Cancer Imaging: The Evolution of PET Scans

EP: 3.Prostate Cancer Imaging: PSMA Agents and Radiotracer Options

Now Viewing

EP: 4.Challenges and Progress in Advanced Imaging for Prostate Cancer

EP: 5.CMS Reimbursement Shift in Prostate Cancer: Streamlining Radiotracer Payments

EP: 6.Prostate Cancer Imaging and Care in 2023: Best Practices

EP: 7.Practical Guidance for Prostate Cancer Imaging: PSMA-PET Scans and Patient Selection

Related Videos

Related Content

Advertisement

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.

Related Content

Advertisement

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.